PILA PHARMA AB (PUBL)
Climate Impact & Sustainability Data (2022)
Reporting Period: 2022
Environmental Metrics
Climate Goals & Targets
Long-term Goals:
- If positive Phase 2b results are achieved, XEN-D0501 could proceed to clinical Phase 3, which in diabetes is testing of the drug candidate in up to 4000 patient-years.
Medium-term Goals:
- Initiate a three-month dose-response study in approximately 250–300 patients with type-2 diabetes (Phase 2b study) in 2023, with expected results in 2024, provided sufficient capital is secured.
Short-term Goals:
- Complete the analytical development activities for XEN-D0501 tablets (planned to be completed in May), with the analysis of tablets and new analysis certificate expected in June 2023.
Environmental Challenges
- Increased inflation and a weak Swedish krona led to increased costs in ongoing projects, increasing the risk of increased capital needs and impacting the company's continued operations.
Mitigation Strategies
- A rights issue in November raised approximately 6.9 MSEK to continue operations towards submitting a clinical phase 2b trial application for diabetes (including new tablet certification).